Clinical Ophthalmology (Nov 2020)
Icare Home Tonometer: A Review of Characteristics and Clinical Utility
Abstract
John Liu,1,2 Ticiana De Francesco,1,2 Matthew Schlenker,1,2 Iqbal Ike Ahmed1,2 1Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada; 2Prism Eye Institute, Oakville, Ontario, CanadaCorrespondence: Iqbal Ike Ahmed Tel +1 (905) 456-3937Email [email protected]: The Icare HOME (TA022, Icare Oy, Vanda, Finland) is rebound tonometer recently approved by the US Food and Drug Administration in March 2017 designed for self-measurement of intraocular pressure (IOP). IOP remains a major modifiable risk factor for glaucoma progression; however, IOP measurements typically occur through single office measurements on Goldmann applanation tonometry (GAT) and do not always reveal the complete picture of patient’s IOP patterns and daily fluctuations, which are important for accurate diagnosis and evaluation. Numerous studies have now compared the efficacy of the Icare HOME to that of GAT. The objective of this article is to review the existing literature surrounding the Icare HOME tonometer and its efficacy as a self-tonometer in comparison to GAT. The available literature has shown promising results in its accuracy of measuring IOP but suggests cautious usage in patients with central corneal thicknesses or IOP ranges that are outside of a certain range. This article will also provide details and example cases for when the Icare HOME may be most clinically useful.Keywords: Icare HOME, Icare, self-tonometry, glaucoma
